Last updated: February 15, 2026
What is the drug corresponding to NDC 42291-0780?
NDC 42291-0780 refers to Imlygic (talimogene laherparepvec), an oncolytic viral therapy developed by Merck (MSD). Approved by the FDA in October 2015, it serves as a treatment for unresectable melanoma with injectable administration.
What is the current market landscape for Imlygic?
Market Size and Penetration
- As of 2023, the US melanoma market is valued at approximately $350 million annually.
- Imlygic accounts for 10-15% of this market, with ongoing competition from immune checkpoint inhibitors such as pembrolizumab (Keytruda) and nivolumab (Opdivo).
- Approximately 2,000 to 3,000 patients in the US are eligible for Imlygic treatment annually, considering the incidence of unresectable melanoma.
Competitive Dynamics
- Competitors include PD-1 inhibitors and combination regimens, which dominate the metastatic melanoma space.
- Imlygic primarily targets localized, injectable tumors, restricting its use to specific patient subsets.
- It faces challenges due to the limited scope of indication and evolving immunotherapy strategies.
Regulatory & Reimbursement Trends
- The drug is reimbursed via Medicare and private insurers. Reimbursement codes include CPT code 902220.
- No recent label expansions or supplemental approvals have been announced since 2018.
- Payers assess its value based on clinical benefit, with some restricting use to specific cases.
Price Analysis
Current Pricing & Cost Structure
- The wholesale acquisition cost (WAC) for Imlygic is approximately $65,000 to $70,000 per treatment course.
- Treatment involves up to 4 doses, with an average cost per patient estimated at $250,000 to $280,000.
Pricing Comparison
| Drug |
Indication |
Approximate Cost per Course |
Usage Scope |
| Imlygic |
Unresectable melanoma |
$70,000 |
Localized, injectable tumors |
| Pembrolizumab |
Advanced melanoma |
$150,000+ |
Systemic, metastatic disease |
| Nivolumab |
Advanced/metastatic melanoma |
$150,000+ |
Systemic, broader indication |
Note: Imlygic's lower cost per course reflects its narrower application scope.
Projected Market Trends and Price Trajectories
Short to Medium Term (Next 3-5 Years)
- Market Volume: Expected growth in patient numbers due to increased diagnosis and earlier detection.
- Use Cases Expansion: Limited clinical research suggests potential for combination therapies with checkpoint inhibitors, potentially expanding indications.
- Pricing Dynamics: Prices are likely to remain stable unless new formulations or approvals emerge; however, cost reductions could occur through negotiations or biosimilar-like manufacturing economies.
Long Term (Beyond 5 Years)
- Market Disruption Risks: Emergence of new oncolytic agents or gene therapies could replace or supplement Imlygic.
- Market Penetration: Increased use may occur if combination protocols prove superior, possibly increasing overall revenue but potentially pressuring unit prices downward due to competitive strategies.
- Regulatory Changes: Policy shifts favoring value-based pricing could influence future price points, especially if efficacy data bolster clinical benefits.
Key Drivers Influencing Market and Pricing
- Clinical Evidence: Real-world data supporting superior outcomes could justify higher pricing or expanded indications.
- Competitive Advances: New therapies, including personalized vaccines or oncolytic agents, could diminish Imlygic’s market share.
- Reimbursement Policies: Budget constraints and value-based models could pressure prices downward.
- Manufacturing Costs: Advances in manufacturing could enable cost reductions, potentially influencing room for price adjustments.
Summary of Price Projections and Market Drivers
| Scenario |
Market Share Outlook |
Price Change Expectation |
Key Factors |
| Conservative |
Stable, slight decline in units sold |
Maintains current levels, small decrease |
Patent stability, limited competition |
| Moderate growth |
Slight increase in utilization |
Flat or slight decrease due to competition |
Clinical data supporting use |
| Aggressive expansion |
Market share increases through label expansion or combo use |
Potential price reductions to sustain volume |
New approvals, better efficacy data |
Key Takeaways
- NDC 42291-0780 (Imlygic) currently commands approximately $70,000 per course in the US.
- The drug's market is constrained by its narrow indication but could expand via combination therapies.
- Market size remains relatively small at 2,000–3,000 US patients annually.
- Price pressures are expected to stabilize unless new indications or competitors alter the landscape.
- Long-term prospects hinge on clinical advances and payer policies.
FAQs
Q1: Will the price of Imlygic decrease significantly in the next five years?
Likely minimal unless large-scale manufacturing cost reductions or policy-driven price controls occur.
Q2: Are there opportunities to expand the use of Imlygic?
Clinical research suggests potential combination therapies and new indications could augment its use.
Q3: How does Imlygic compare with other immunotherapies cost-wise?
It is less expensive per treatment course than systemic agents like pembrolizumab or nivolumab, but its narrower efficacy scope limits its market penetration.
Q4: What factors could influence reimbursement rates?
Clinical outcomes, comparative effectiveness, and policy shifts toward value-based pricing.
Q5: Is there potential for biosimilar competition?
Currently unlikely due to unique viral vector manufacturing complexities and data exclusivity.
Sources
[1] FDA, Imlygic labeling updates, 2015-2022.
[2] IQVIA Market Insights, 2022.
[3] Medicare and private payer reimbursement data, 2023.
[4] ClinicalTrials.gov, ongoing research on oncolytic therapies.
